The purpose of this study is to determine progression-free survival (PFS) in participants with unresectable hepatocellular carcinoma who have received no prior systemic therapy when treated with IMC-A12 administered every three weeks in combination with oral sorafenib administered twice daily.
To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.